Clinical Trials
7 trialsNCT03613532 2026-05-20
Venetoclax Added to Fludarabine + Busulfan Prior to Transplant and to Maintenance Therapy for AML, MDS, and MDS/MPN
Dana-Farber Cancer Institute
Phase 1 Active not recruiting
NCT04975919 2026-05-14
Venetoclax in Combination With Decitabine and Cedazuridine for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT05600894 2026-05-13
Venetoclax in Combination With ASTX727 for the Treatment of Chronic Myelomonocytic Leukemia and Other Myelodysplastic Syndrome/Myeloproliferative Neoplasm
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT02998567 2026-05-12
HyPeR
Royal Marsden NHS Foundation Trust
Phase 1 Active not recruiting
NCT05396859 2026-04-27
Entrectinib in Combination With ASTX727 for the Treatment of Relapsed/Refractory TP53 Mutated Acute Myeloid Leukemia
OHSU Knight Cancer Institute
Phase 1 Active not recruiting
NCT04980404 2026-03-30
Inqovi Maintenance Therapy in Myeloid Neoplasms
Massachusetts General Hospital
Phase 1 Active not recruiting
NCT04746235 2026-03-12
Venetoclax and ASTX727 for the Treatment of Relapsed, Refractory, or Newly Diagnosed Acute Myeloid Leukemia
M.D. Anderson Cancer Center
Phase 2 Active not recruiting